Novel Agents Under Evaluation for HER2+ Breast Cancer and Brain Metastases

Findings from the phase 3 DAWNA-2 trial suggest that dalpiciclib plus endocrine therapy may be a potential novel first-line treatment option for hormone receptor–positive, HER2-negative advanced breast cancer.

Rakhshanda Rahman, MD, FRCS, FACS, emphasizes the importance of educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.

Data from a phase 3 study indicate that weight loss intervention with a telephone-based program appears to be effective across all subgroups of breast cancer survivors.

Minh-Tri Nguyen, MD, spoke with CancerNetwork® about differences between time to treatment, socioeconomic status, and clinical outcomes in rural and urban patients with breast cancer.

The FDA also accepts a premarket approval application for the Lumicell Direct Visualization System in the breast cancer space.

Hospitalization rates appear to be comparable between patients receiving trastuzumab deruxtecan and trastuzumab emtansine for HER2-positive breast cancer in the phase 3 DESTINY-Breast03 study.